



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRUENBERG

Serial No.: 09/127,411

Filed: July 31, 1998

For: *AUTOLOGOUS IMMUNE CELL  
THERAPY: CELL  
COMPOSITIONS, METHODS  
AND APPLICATIONS TO  
TREATMENT OF HUMAN  
DISEASE*

Art Unit: 1644

Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231, on this date.

10/22/98

Date

*Kathy Holloway*  
Kathy Holloway

TRANSMITTAL LETTER

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Transmitted herewith is an Information Disclosure Statement and Forms PTO-1449 (14 pages) for filing in connection with the above-identified application. Because this Information Disclosure Statement is filed prior to receipt of a first office action on the merits in the above-referenced application, no fee is due. However, should it be determined that a fee for filing these papers is required, the Commissioner is authorized to charge Deposit Account Number 08-1641, as stated below:

( X ) The Commissioner is hereby authorized to charge the fee for the Information Disclosure Statement and any other fees that may be due under 37 C.F.R. §§1.16-1.17 in connection with this paper or with this application during its entire pendency to Deposit Account No. 08-1641. A duplicate of this sheet is enclosed.

Respectfully submitted,  
HELLER, EHRMAN, WHITE & McAULIFFE

By:

*Stephanie L. Seidman*  
Stephanie L. Seidman  
Registration No. 33,779

Attorney Docket No. 24731-500C  
Address all correspondence to:  
HELLER, EHRMAN, WHITE & McAULIFFE  
4250 Executive Square,  
La Jolla, California 92037  
Telephone: (619) 450-8400  
EMAIL sseidman@hewm.com

RECEIVED  
TECH. DIV. 1  
OCT 23 1998  
8:24



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: GRUENBERG  
Serial No.: 09/127,411  
Filed: July 31, 1998  
For: *AUTOLOGOUS IMMUNE CELL  
THERAPY: CELL COMPOSITIONS,  
METHODS AND APPLICATIONS TO  
TREATMENT OF HUMAN DISEASE*  
Art Unit: 1644  
Examiner: Unassigned

I hereby certify that this paper and the attached papers are being deposited with the United States Postal Service as first class mail in an envelope addressed to:

Assistant Commissioner for Patents  
Washington, D.C. 20231, on this date.

10/22/98  
Date

*Kathy Holloway*  
Kathy Holloway

INFORMATION DISCLOSURE STATEMENT  
IN ACCORDANCE WITH 37 C.F.R. §§ 1.97-1.98

Assistant Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

Because this Information Disclosure Statement is filed prior to receipt of a First Office Action on the Merits for the above-captioned application, a fee for filing this statement should not be due. If, however, it is determined that a fee is due, any fees that may be due in connection with filing this paper may be charged to Deposit Account No. 08-1641.

In accordance with the duty of disclosure imposed by 37 C.F.R. §1.56 to inform the Patent Office of all references known by Applicant or Applicant's representative that may be material to the examination of the subject application, Applicant's representative hereby provides this Information Disclosure Statement that is prepared in accordance with 37 C.F.R. §§1.97-1.98. Forms PTO-1449 (14 pages) are provided herewith. Copies of the references listed on the Form PTO-1449 are not provided herewith as they have been previously provided in connection with U.S. Serial No. 08/700,565, which claims priority of Provisional U.S. Application Serial No. 60/044,693 (converted from 08/506,668), and which is relied upon for an earlier filing date in accordance with 35 U.S.C. §120. The documents that are cited in connection with this application are in the English language. Hence, in accordance with the

RECEIVED  
TECH. CENTER 1000/2900  
93 OCT 28 AM 8:25

**U.S.S.N. 09/127,411**  
**GRUENBERG**  
**INFORMATION DISCLOSURE STATEMENT**

requirements of 37 C.F.R. §1.98, as amended effective March 16, 1992, no further explanation of the listed items is necessary.

Although these documents are made known to the Patent and Trademark Office in compliance with Applicant's duty of disclosure, such disclosure is not to be construed as an admission by Applicant or Applicant's representative that any of the references is effective as prior art against the subject application. In accordance with 37 C.F.R. §1.97(h), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 C.F.R. §1.56(b) exists.


Applicant also makes known to the Examiner the following related, co-pending applications:

<u>U.S.S.N.</u>	<u>Inventor</u>	<u>Filing Date</u>
09/127,142	GRUENBERG	7/31/98
09/127,138	GRUENBERG	7/31/98
09/127,141	GRUENBERG	7/31/98
 <u>PCT Application Serial No.</u>	 <u>Inventor</u>	 <u>Filing Date</u>
PCT/US96/12170	GRUENBERG	7/24/96

Applicant respectfully requests that the Examiner review the foregoing references and that they be made of record in the file history of the above-captioned application.

Respectfully submitted,  
HELLER, EHRMAN, WHITE & McAULIFFE

By:

  
Stephanie L. Seidman  
Registration No. 33,779

Attorney Docket No. 24731-500C  
Address all correspondence to:  
HELLER, EHRMAN, WHITE & McAULIFFE  
4250 Executive Square, Suite 700,  
La Jolla, California 92037  
Telephone: (619) 450-8403  
EMAIL sseidman@hewm.com